Molecular Partners AG ADR (MOLN) — Capital Reinvestment Ratio
Latest as of March 2022:
0.00x
Molecular Partners AG ADR (MOLN) has a Capital Reinvestment Ratio of 0.00x as of March 2022, meaning it reinvests 0% of its operating cash flow ($163.56 Million) in capital expenditures ($380.00K). See Molecular Partners AG ADR (MOLN) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$163.56 Million
USD
Capital Expenditures
$380.00K
USD
Data as of
Mar 2022
Most recent filing
Molecular Partners AG ADR Capital Reinvestment Ratio (2015–2022)
This chart tracks Molecular Partners AG ADR's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Molecular Partners AG ADR (2015–2022)
Year-by-year Capital Reinvestment Ratio for Molecular Partners AG ADR from 2015 to 2022. For live market cap and broader valuation context, see market cap of Molecular Partners AG ADR.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.01x | $118.57 Million | $1.42 Million | ▼ -77.2% |
| 2015 | 0.05x | $26.50 Million | $1.39 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow